PHILADELPHIA, July 14, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN) on behalf of purchasers of Organon securities between November 3, 2022 through April 30, 2025, inclusive (the "Class Period"). Contact: Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff repre ...

NEW YORK, July 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline.So what: If you purchased Hims common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What ...

Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH), a condition marked by dangerously low blood sugar following weight-loss surgery. Read Next: Image: Shutterstock Previous trials, including Phase 2 PREVENT and Phase 2b, showed consistent, dose-dependent reductions in these ...

Bristol-Myers Squibb & Co. BMY is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.While revenue and underlying earnings per share estimates for the current quarter and full-year 2025 have seen slight downward revisions, the U.S. pharma giant anticipates a low-single-digit percentage increase in total revenue for the later 2020s, primarily driven by updated assumptio ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Exelixis (EXEL) is highlighted as a promising growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 28.3%, with projected EPS growth of 31.8% this year, surpassing the industry average of 19.8% [5] - Exelixis has achieved a year-over-year cash flow growth of 135.6%, significantly higher than the industry average of -4.5% [6] Group 2: Financial Metrics - Earnings growth is crucial for attracting investor attention, with double-digit growth being particularly favorable [4] - The annualized cash flow growth rate for Exelixis over the past 3-5 years is 10.8%, compared to the industry average of 3.7% [7] - There has been a positive trend in earnings estimate revisions for Exelixis, with a 1.3% increase in the current-year earnings estimates over the past month [9] Group 3: Investment Positioning - Exelixis has earned a Growth Score of A and a Zacks Rank 2 due to positive earnings estimate revisions, positioning it well for potential outperformance [11]

Key Takeaways GSK's Arexvy filing seeks FDA approval for use in high-risk adults under age 50. Late-stage trial data showed Arexvy's safety matched results from previous vaccine studies. Arexvy's sales dropped 51% in 2024 amid tighter U.S. guidelines and rising vaccine competition.GSK plc (GSK) announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision is expected in the first ...

Eledon Pharmaceuticals, Inc. (ELDN) : This clinical stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 23.8% over the last 60 days. Eledon's shares gained 22.2% over the past month compared with the S&P 500's advance of 3.8%. The company possesses a Momentum Score of A. Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 14th: KDDI Corporation (KDDIY) : This Japanese tel ...

Tylenol parent Kenvue Inc (NASDAQ:KVUE) is up 1.4% to trade at $21.64, after the company fired its CEO Thibaut Mongon amid efforts to revamp performance. Mongon also stepped down from his position on the board, as Kirk Perry was named interim CEO. This marks the second C-suite shakeup for Kenvue this year, after Chief Financial Officer (CFO) Paul Ruh was replaced with Amit Banati in May. The company also said tariffs could create a negative impact of up to $150 million.KVUE is eyeing a fourth-straight win, ...

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executiv ...

Bain Capital has agreed to make an investment in PCI Pharma Services, a drug services provider that helps assemble and package medicines https://t.co/KK8mEiFPx6 ...